This profile was last updated on //
Is this you? Claim your profile.
Immune Response BioPharma Inc
2711 Centerville Road Suite 400
Immune Response BioPharma, Inc.Â TMÂ is a Delaware corporation and is a leading vaccine development company that has its own proprietary drug pipeline under development and currently owns 100% of its drugs and vaccine treatments. Development of current dr
(14 Total References)
Chief Operating Officer & Chief Financial Officer & CEO: Mr. David Buswell
Mr. David Buswell is founder of Immune Response BioPharma, and is Chief Operating Officer, CFO, PresidentÂ & acting CEO and is Chairman of the Board of Directors.
Mr. Buswell holds a Bachelorâ€™s degree in Business & Commerce from the University of Mary Washington, and a Masterâ€™s degree MA in Management & Leadership from Liberty University.
Orphan designation will allow for a ...
Orphan designation will allow for a more speedy development of RAVAX and will give us further flexibility in trial design and expand the RA vaccine use into the rare disease, JRA [juvenile RA], said David Buswell, Chief Operating Officer and Interim Chief Executive Officer of Immune Response BioPharma.
In the Pipeline:
Update: Immune Response Biopharma CEO David Buswell has left a detailed comment to this point, pointing out that it was his company that ended talks with GSK, and not the other way around.
See here for the details.
GSK has no approved MS drug and probably will never have one they are busy wasting their shareholders money on HGSI and a Lupus drug with poor sales, we don't need them or to give away our blockbuster drug for MS to them which we believe will become treatment of choice" IRBP CEO Mr. Buswell
values NeuroVax north of a billion dollar of annual sales once approved.
We will find a solid partner or raise capital on our own, we don't need GSK
which has zer0 experience in multiple sclerosis or auto-immune diseases.
is a joke and seems very ignorant on how multiple sclerosis drugs work and how to develop one, we gave them a chance to develop NeuroVax but their management appears to be very poor.
We have decided to terminate any collaboration or development with GSK
GSK is a loser in the MS market and will continue to be a loser" IRBP CEO Mr. Buswell
Y'know, in his
way, this CEO is a breath of fresh air.
Everyone thinks these things in such situations, but not many people put them out on the PR wires.
This release seems to have transcribed directly from Mr. Buswell's
(no doubt heated) statements at the time, which I'm sure accounts for the take-a-breath grammar.
David Buswell, the chief ...
David Buswell, the chief executive of Immune Response Biopharma, has let rip at GlaxoSmithKline in the wake of an apparently acrimonious breakdown in talks over a tie-up involving a multiple sclerosis drug.
Mr Buswell accused GSK's Sir Andrew Witty of 'wasting money' on a £2.6 billion takeover bid for Human Genome Sciences and of devoting resources to the newly approve Benlysta, 'a lupus drug with poor sales'.
"This recent issuance of U.S. 8,053,197 ...
"This recent issuance of U.S. 8,053,197 is a key patent in that it extends key IP coverage including FOXP3+ Expression Technology related to the delivery and composition of NeuroVax with TCR peptide vaccines including the addition of estrogen to boost the vaccine potential in women suffering from MS." said Mr. David Buswell, IRBP Chief Executive Officer.
Immune Response BioPharma, Inc.
244 5th avenue suite 1727